saline + glucose

"Saline + glucose" is an inert placebo formulation used as a comparator in clinical trials, specifically in a Phase 2 study (NCT01883440) investigating a glucose oxidase nasal spray for the treatment of the common cold. The formulation consists of an isotonic saline solution supplemented with 5% glucose, delivered via a nasal spray. In the context of the trial led by Krister Tano at Umeå University, it serves as the control arm against an active treatment that utilizes glucose oxidase to enzymatically produce virucidal hydrogen peroxide. As a placebo, it lacks an active pharmaceutical ingredient and has no defined biological target or therapeutic effect.

Other names

isotonic saline with 5% glucose